SNL Stock Overview Develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Smith & Nephew plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Smith & Nephew Historical stock prices Current Share Price UK£9.86 52 Week High UK£12.45 52 Week Low UK£9.11 Beta 0.69 1 Month Change 0.15% 3 Month Change -15.34% 1 Year Change -8.33% 3 Year Change -23.51% 5 Year Change -46.27% Change since IPO 61.09%
Recent News & Updates
Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Dec 19
Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025 Nov 02
Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025 Oct 31
Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium) Oct 02
Smith+Nephew Announces Board and Committee Changes Sep 27 Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024 See more updates
Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Dec 19
Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025 Nov 02
Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025 Oct 31
Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium) Oct 02
Smith+Nephew Announces Board and Committee Changes Sep 27 Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024
Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System Jul 17 Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.). Jul 05
Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024 May 10
Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024 May 01
Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System Apr 02 Smith & Nephew plc Announces Board Changes
Upcoming dividend of US$0.23 per share Mar 22
Smith & Nephew plc, Annual General Meeting, May 01, 2024 Mar 12
Final dividend of US$0.23 announced Mar 01 Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024
Full year 2023 earnings released: EPS: US$0.30 (vs US$0.26 in FY 2022) Feb 29 Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting
Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial Jan 11
Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd. Jan 10
Smith+Nephew Announces Board Changes Dec 07
Smith+Nephew Announces Board Changes Dec 06
Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million. Nov 23
Smith & Nephew plc Provides Earning Guidance for Full Year 2023 Nov 04
Smith & Nephew plc Announces Appointment of John Rogers as CFO Nov 02
Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023 Oct 21
Upcoming dividend of US$0.14 per share at 3.0% yield Sep 28
Smith & Nephew plc Announces Board and Committee Changes Sep 14
Smith & Nephew plc Increases Revenue Guidance for 2023 Aug 04
First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022) Aug 04
Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer Aug 03
Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System Jun 13
Chief Human Resources Officer recently sold UK£51k worth of stock May 26
Now 22% undervalued May 24
Now 20% undervalued May 03
Insider recently bought UK£117k worth of stock Apr 30
Upcoming dividend of US$0.23 per share at 2.6% yield Mar 23
Chief Human Resources Officer recently sold UK£111k worth of stock Mar 15
Full year 2022 earnings released: EPS: US$0.26 (vs US$0.60 in FY 2021) Feb 23 Smith & Nephew plc, Annual General Meeting, Apr 26, 2023
Now 21% undervalued Dec 02
High number of new directors Nov 16
Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023 Nov 04
Smith & Nephew plc Announces Revenue Guidance for 2022 Nov 03
Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution Nov 02
Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform Sep 27
Upcoming dividend of US$0.14 per share Sep 22
Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty Sep 20
Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair Sep 15 Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023
Smith & Nephew plc Announces Executive Changes Sep 01
Chairman recently bought UK£59k worth of stock Aug 28
First half 2022 earnings released Jul 29 Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022
Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care Jul 12
Smith & Nephew plc Announces Executive Changes Jun 21
Smith & Nephew plc Announces Executive Changes Jun 20
Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation Jun 09
High number of new directors Apr 27
Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors Apr 01
Upcoming dividend of US$0.23 per share Mar 24
Independent Non-Executive Director recently bought UK£59k worth of stock Mar 09
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Smith & Nephew plc, Annual General Meeting, Apr 13, 2022 Feb 24 Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022
Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION Jan 27
Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems Jan 25
Smith & Nephew plc (LSE:SN.) acquired Engage Surgical. Jan 19
Now 24% undervalued Jan 13
Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares. Dec 17
Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada Nov 27
Smith+Nephew Launches CORI Handheld Robotics Nov 24
Insider recently sold UK£160k worth of stock Nov 19
Upcoming dividend of US$0.14 per share Sep 23
Insider recently sold UK£322k worth of stock Sep 17 Smith+Nephew Introduces Pioneering New Technologies for Its Journey II Total Knee Arthroplasty Portfolio
Key Executive recently sold UK£75k worth of stock Aug 25
Smith+Nephew Announces Launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand Aug 18
Insider recently sold UK£133k worth of stock Aug 06
First half 2021 earnings released: EPS US$0.23 (vs US$0.12 in 1H 2020) Jul 30
Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears Jul 23
Smith+Nephew Launches ARIA Home PT, a Remote Physical Therapy Solution May 06
Key Executive recently sold UK£138k worth of stock May 05 Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021
Independent Non-Executive Director has left the company Apr 16
Upcoming dividend of US$0.23 per share Mar 25
President of Sports Medicine & ENT recently sold UK£97k worth of stock Mar 20 Shareholder Returns SNL GB Medical Equipment GB Market 7D 1.0% -0.5% -0.6% 1Y -8.3% -9.6% 2.7%
See full shareholder returns
Return vs Market: SNL underperformed the UK Market which returned 3.1% over the past year.
Price Volatility Is SNL's price volatile compared to industry and market? SNL volatility SNL Average Weekly Movement 4.5% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: SNL has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SNL's weekly volatility (5%) has been stable over the past year.
About the Company Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Show more Smith & Nephew plc Fundamentals Summary How do Smith & Nephew's earnings and revenue compare to its market cap? SNL fundamental statistics Market cap UK£8.60b Earnings (TTM ) UK£243.02m Revenue (TTM ) UK£4.50b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SNL income statement (TTM ) Revenue US$5.64b Cost of Revenue US$1.67b Gross Profit US$3.97b Other Expenses US$3.66b Earnings US$305.00m
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) 0.35 Gross Margin 70.33% Net Profit Margin 5.41% Debt/Equity Ratio 66.7%
How did SNL perform over the long term?
See historical performance and comparison Dividends
3.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 02:43 End of Day Share Price 2024/12/24 00:00 Earnings 2024/06/29 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Smith & Nephew plc is covered by 57 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kamla Singh AlphaValue Christoph Gubler Bank Vontobel AG Hassan Al-Wakeel Barclays
Show 54 more analysts 
